T
Toripalimab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Medication Guide
Subsidy Information and Financing Scheme
No
Active ingredient: Toripalimab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combination with chemotherapy for inclusion on the MOH List of Subsidised Drugs for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma. The decision was based on the unfavourable cost effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for toripalimab plus chemotherapy are provided in the Annex.